Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO

Launched by ·

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called IBI311 for people with inactive thyroid-associated ophthalmopathy (TAO), a condition linked to thyroid disease that affects the eyes. TAO can cause symptoms like eye swelling, discomfort, and in severe cases, vision problems or even blindness. IBI311 is a type of medicine designed to block certain signals in the body that cause eye tissue to grow and swell. Researchers want to see if IBI311 is both effective and safe for people with moderate to severe TAO that is currently inactive, meaning the disease isn’t actively worsening.

The study is open to adults with inactive moderate to severe TAO. Participants will receive IBI311 treatment and be closely monitored to see how well the medicine works and if there are any side effects. This trial aims to fill gaps in current knowledge about using IBI311 in this group of patients. If you or a loved one has inactive TAO and are interested in new treatment options, this study might be an opportunity to consider.

Gender

ALL

Eligibility criteria